Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3764) 3764
Publication (243) 243
Newsletter (30) 30
Book Review (20) 20
Book Chapter (8) 8
Magazine Article (7) 7
Conference Proceeding (4) 4
Dissertation (4) 4
Newspaper Article (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1990) 1990
animals (1845) 1845
male (1829) 1829
index medicus (1513) 1513
female (1462) 1462
benzoates - administration & dosage (1284) 1284
benzoates - pharmacology (1039) 1039
benzoates - therapeutic use (982) 982
rats (911) 911
pharmacology & pharmacy (690) 690
adult (641) 641
middle aged (617) 617
mice (541) 541
administration, oral (415) 415
benzoates - adverse effects (414) 414
aged (410) 410
time factors (378) 378
telmisartan (377) 377
benzimidazoles - administration & dosage (374) 374
treatment outcome (374) 374
dose-response relationship, drug (373) 373
benzimidazoles - therapeutic use (305) 305
hypertension - drug therapy (277) 277
adolescent (274) 274
rats, sprague-dawley (272) 272
benzoates - pharmacokinetics (269) 269
hypertension (265) 265
hematology (257) 257
blood pressure - drug effects (250) 250
estradiol benzoate (238) 238
benzoic acid (236) 236
benzimidazoles - pharmacology (235) 235
drug therapy, combination (234) 234
sodium benzoate (221) 221
benzoates - chemistry (216) 216
rats, wistar (215) 215
research (213) 213
benzoates (212) 212
child (205) 205
disease models, animal (196) 196
triazoles - administration & dosage (194) 194
triazoles - therapeutic use (189) 189
analysis (188) 188
neurosciences (180) 180
angiotensin ii type 1 receptor blockers - administration & dosage (177) 177
biochemistry & molecular biology (176) 176
iron chelating agents - therapeutic use (176) 176
oncology (174) 174
estradiol - pharmacology (171) 171
deferasirox (169) 169
iron chelating agents - administration & dosage (169) 169
pregnancy (167) 167
benzoates - metabolism (166) 166
pharmacokinetics (164) 164
iron overload - drug therapy (162) 162
angiotensin ii type 1 receptor blockers - therapeutic use (161) 161
double-blind method (160) 160
health aspects (160) 160
expression (158) 158
care and treatment (156) 156
drug combinations (156) 156
peripheral vascular disease (155) 155
drug therapy (150) 150
antihypertensive agents - administration & dosage (144) 144
efficacy (144) 144
oxidative stress (140) 140
young adult (137) 137
estradiol - administration & dosage (135) 135
pyrazoles - therapeutic use (135) 135
child, preschool (134) 134
hydrazines - therapeutic use (134) 134
angiotensin ii type 1 receptor blockers - pharmacology (131) 131
toxicology (131) 131
metabolism (130) 130
safety (130) 130
dosage and administration (125) 125
pyrazoles - administration & dosage (125) 125
antihypertensive agents - therapeutic use (124) 124
endocrinology & metabolism (123) 123
receptors, thrombopoietin - agonists (123) 123
therapy (122) 122
article (120) 120
inflammation (120) 120
medicine, general & internal (118) 118
hydrazines - administration & dosage (117) 117
mice, inbred c57bl (116) 116
rodents (114) 114
benzimidazoles - adverse effects (113) 113
angiotensin-converting enzyme inhibitors - administration & dosage (112) 112
medicine (112) 112
eltrombopag (111) 111
monoterpenes (111) 111
research article (111) 111
liver - metabolism (110) 110
benzoates - blood (109) 109
dogs (109) 109
medicine, research & experimental (108) 108
double-blind (107) 107
purpura, thrombocytopenic, idiopathic - drug therapy (107) 107
drug administration schedule (106) 106
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3457) 3457
German (100) 100
Russian (59) 59
Japanese (51) 51
French (41) 41
Chinese (35) 35
Italian (19) 19
Spanish (16) 16
Polish (8) 8
Czech (5) 5
Danish (4) 4
Hungarian (3) 3
Portuguese (3) 3
Bulgarian (2) 2
Dutch (2) 2
Norwegian (2) 2
Romanian (2) 2
Serbian (1) 1
Slovak (1) 1
Slovenian (1) 1
Swedish (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Simultaneous determination of five phenolic components and paeoniflorin in rat plasma by liquid chromatography–tandem mass spectrometry and pharmacokinetic study after oral administration of Cerebralcare granule
by Wang, Xiang-yang and Wang, Jun-mei and Ma, Xiao-hui and Li, Shu-ming and Li, Wei and Chu, Yang and Guo, Jia-hua and Zhang, Hong-chao and Zhou, Shui-ping and Zhu, Yong-hong
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 12/2013, Volume 86, pp. 82 - 91
Chromatograms of the six active components and IS in plasma: plasma sample obtain 45 min after oral administration of CG (20 g/kg). Peak 1, PCA; Peak 2, CA;... 
Cerebralcare granule | Active components | Pharmacokinetics | LC–MS/MS | Rat plasma | LC-MS/MS | SAN | CHEMISTRY, ANALYTICAL | DANSHENSU | INJURY | CRYPTOTANSHINONE | Cerebralcare granule (R) | FERULIC ACID | CHLOROGENIC ACID | INJECTION | TANSHINONE IIA | PHARMACOLOGY & PHARMACY | POWDER | HPLC | Glucosides - blood | Rats, Wistar | Administration, Oral | Rats | Male | Glucosides - pharmacokinetics | Paeonia | Drugs, Chinese Herbal - pharmacokinetics | Benzoates - blood | Animals | Phenols - pharmacokinetics | Bridged-Ring Compounds - blood | Phenols - blood | Monoterpenes | Drugs, Chinese Herbal - administration & dosage | Chromatography, Liquid - methods | Bridged-Ring Compounds - pharmacokinetics | Tandem Mass Spectrometry - methods | Benzoates - pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Tissue distribution, metabolism and hepatic tissue injury in Chinese lizards (Eremias argus) after a single oral administration of lambda-cyhalothrin
by Chang, Jing and Li, Wei and Li, Jianzhong and Li, Jitong and Wang, Huili and Wang, Yinghuan and Guo, Baoyuan and Yin, Jing and Hao, Weiyu and Xu, Peng
Environmental Pollution, ISSN 0269-7491, 11/2016, Volume 218, pp. 965 - 972
Lambda-cyhalothrin (LCT) is a widely used pyrethroid with neurotoxicity. However, little is known about the toxicokinetics of LCT in reptiles. In this study,... 
Histopathology | Metabolism | Lizard | Lambda-cyhalothrin | Distribution | WESTERN FENCE LIZARD | TOXICITY | STEREOSELECTIVE DEGRADATION | 1ST-PASS METABOLISM | ENVIRONMENTAL SCIENCES | TOXICOKINETICS | PYRETHROID INSECTICIDE | BETA-CYPERMETHRIN | ECOLOGICAL RISK | ENANTIOSELECTIVE DEGRADATION | 3-PHENOXYBENZOIC ACID | Nitriles - toxicity | Pyrethrins - toxicity | Liver - pathology | Administration, Oral | Skin - metabolism | Stereoisomerism | Benzoates - metabolism | Liver - metabolism | Half-Life | Birds | Male | Nitriles - pharmacokinetics | Pyrethrins - pharmacokinetics | Brain - metabolism | Tissue Distribution | Adipose Tissue - metabolism | Animals | Lizards - blood | Chemical and Drug Induced Liver Injury - pathology | Insecticides - toxicity | Lizards - metabolism | Benzoates - pharmacokinetics | Insecticides - pharmacokinetics | Physiological aspects | Skin | Metabolites | Enantiomers | Lizards | Liver | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Hematopoietic growth factors in myelodysplastic syndromes
by Steensma, David P
Seminars in Oncology, ISSN 0093-7754, 10/2011, Volume 38, Issue 5, pp. 635 - 647
Hematopoietic growth factors (HGFs) continue to be the most widely prescribed class of medications for patients with myelodysplastic syndromes (MDS), despite... 
TUMOR-NECROSIS-FACTOR | LOW-RISK | COLONY-STIMULATING FACTOR | ONCOLOGY | GM-CSF | RECOMBINANT-HUMAN-ERYTHROPOIETIN | ERYTHROID RESPONSE | TRANS-RETINOIC ACID | QUALITY-OF-LIFE | INTERNATIONAL WORKING GROUP | DARBEPOETIN-ALPHA | Recombinant Proteins - therapeutic use | Benzoates - adverse effects | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Erythropoietin - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Erythropoietin - adverse effects | Thrombopoietin - therapeutic use | Recombinant Proteins - adverse effects | Thrombopoietin - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Filgrastim | Patient Selection | Receptors, Fc - therapeutic use | Erythropoietin - analogs & derivatives | Drug-Related Side Effects and Adverse Reactions | Colony-Stimulating Factors - adverse effects | Epoetin Alfa | Hydrazines - administration & dosage | Myelodysplastic Syndromes - drug therapy | Recombinant Fusion Proteins - administration & dosage | Colony-Stimulating Factors - therapeutic use | Pyrazoles - adverse effects | Granulocyte Colony-Stimulating Factor - adverse effects | Erythropoietin - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Hydrazines - therapeutic use | Hematinics - therapeutic use | Polyethylene Glycols | Hematinics - adverse effects | Granulocyte Colony-Stimulating Factor - therapeutic use | Hematinics - administration & dosage | Recombinant Proteins - administration & dosage | Benzoates - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects | Pyrazoles - administration & dosage | Thrombopoietin - adverse effects | Receptors, Fc - administration & dosage | Darbepoetin alfa | Colony-Stimulating Factors - administration & dosage | Granulocyte Colony-Stimulating Factor - administration & dosage | Hydrazines - adverse effects
Journal Article
Details down arrow
4. Full Text Inhaled Agonists of Soluble Guanylate Cyclase Induce Selective Pulmonary Vasodilation
by Evgenov, Oleg V and Kohane, Daniel S and Bloch, Kenneth D and Stasch, Johannes-Peter and Volpato, Gian P and Bellas, Evangelia and Evgenov, Natalia V and Buys, Emmanuel S and Gnoth, Mark J and Graveline, Amanda R and Liu, Rong and Hess, Dean R and Langer, Robert and Zapol, Warren M
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 12/2007, Volume 176, Issue 11, pp. 1138 - 1145
Rationale: Nitric oxide-independent agonists of soluble guanylate cyclase (sGC) have been developed. Objectives: We tested whether inhalation of novel... 
BAY 41-2272 | BAY 58-2667 | Pulmonary hypertension | BAY 41-8543 | Soluble guanylate cyclase | LARGE POROUS PARTICLES | AUGMENTS | pulmonary hypertension | INHALATION | soluble guanylate cyclase | DELIVERY | INHIBITION | ACTIVATOR | RESPIRATORY SYSTEM | BAY-41-2272 | NITRIC-OXIDE | AWAKE LAMBS | HYPERTENSION | CRITICAL CARE MEDICINE | Oxadiazoles - administration & dosage | Injections, Intravenous | Nitric Oxide - pharmacology | Purinones - administration & dosage | Dose-Response Relationship, Drug | Quinoxalines - pharmacology | Oxadiazoles - pharmacology | Lung - metabolism | Pyrazoles - pharmacology | Powders | Pyridines - administration & dosage | Quinoxalines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Administration, Inhalation | Morpholines - pharmacology | Phosphodiesterase Inhibitors - pharmacology | Soluble Guanylyl Cyclase | Receptors, Cytoplasmic and Nuclear - agonists | Pyrimidines - pharmacology | Nitric Oxide - administration & dosage | Benzoates - administration & dosage | Particle Size | Phosphodiesterase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Animals | Cyclic GMP - metabolism | Guanylate Cyclase | Lung - drug effects | Aerosols | Benzoates - pharmacology | Purinones - pharmacology | Sheep | Pulmonary Circulation - drug effects | Pyridines - pharmacology | Vasodilation - drug effects | Drug Combinations | H. Pulmonary Vascular Disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia
by Ehrlich, Lori A and Kwitkowski, Virginia E and Reaman, Gregory and Ko, Chia‐Wen and Nie, Lei and Pazdur, Richard and Farrell, Ann T
Pediatric Blood & Cancer, ISSN 1545-5009, 12/2017, Volume 64, Issue 12, pp. e26657 - n/a
The U.S. Food and Drug Administration (FDA) approved eltrombopag for pediatric patients with chronic immune (idiopathic) thrombocytopenia (ITP) ages ≥6 on June... 
immune thrombocytopenic purpura | Promacta | eltrombopag | pediatric | MULTICENTER | ONCOLOGY | PURPURA | ADULTS | PEDIATRICS | HEMATOLOGY | CHILDREN | Thrombocythemia, Essential - drug therapy | Hydrazines - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | United States | Humans | Child, Preschool | Infant | Male | Drug Approval | Benzoates - administration & dosage | Pyrazoles - administration & dosage | Adolescent | Female | Child | Chronic Disease | Hydrazines - administration & dosage | United States Food and Drug Administration | Thrombocytopenia | Pediatrics | Children | Health aspects | Drug approval | Corticoids | Regulatory agencies | Immunoglobulins | Corticosteroids | Clinical trials | FDA approval | Patients | Splenectomy | Antidepressants | Risk assessment | Age
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Pulmonary administration of Am80 regenerates collapsed alveoli
by Sakai, Hitomi and Horiguchi, Michiko and Ozawa, Chihiro and Akita, Tomomi and Hirota, Keiji and Shudo, Koichi and Terada, Hiroshi and Makino, Kimiko and Kubo, Hiroshi and Yamashita, Chikamasa
Journal of Controlled Release, ISSN 0168-3659, 12/2014, Volume 196, pp. 154 - 160
Chronic obstructive pulmonary disease (COPD) is an intractable pulmonary disease, which causes widespread and irreversible alveoli collapse. Nevertheless,... 
Alveolar regeneration | Chronic obstructive pulmonary disease | Pulmonary administration | Am80 (Tamibarotene) | ELASTASE-INDUCED EMPHYSEMA | LUNG | STEM-CELLS | TRANS-RETINOIC ACID | INDUCTION | IDENTIFICATION | CHEMISTRY, MULTIDISCIPLINARY | BINDING PROTEINS | DISEASE | PHARMACOLOGY & PHARMACY | MICE | EXPRESSION | Epithelial Cells - drug effects | Humans | Pulmonary Emphysema - pathology | Pulmonary Emphysema - drug therapy | Receptors, Retinoic Acid - metabolism | Pulmonary Disease, Chronic Obstructive - pathology | Benzoates - administration & dosage | Regeneration - drug effects | Animals | Tetrahydronaphthalenes - administration & dosage | Cell Differentiation - drug effects | Tetrahydronaphthalenes - pharmacology | Pulmonary Disease, Chronic Obstructive - chemically induced | Benzoates - pharmacology | Pancreatic Elastase | Pulmonary Alveoli - drug effects | Stem Cells - drug effects | Mice | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | DNA microarrays | Analysis | Stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke
by Sacco, Ralph L and Diener, Hans-Christoph and Yusuf, Salim and Cotton, Daniel and Ôunpuu, Stephanie and Lawton, William A and Palesch, Yuko and Martin, Reneé H and Albers, Gregory W and Bath, Philip and Bornstein, Natan and Chan, Bernard P.L and Chen, Sien-Tsong and Cunha, Luis and Dahlöf, Björn and De Keyser, Jacques and Donnan, Geoffrey A and Estol, Conrado and Gorelick, Philip and Gu, Vivian and Hermansson, Karin and Hilbrich, Lutz and Kaste, Markku and Lu, Chuanzhen and Machnig, Thomas and Pais, Prem and Roberts, Robin and Skvortsova, Veronika and Teal, Philip and Toni, Danilo and VanderMaelen, Cam and Voigt, Thor and Weber, Michael and Yoon, Byung-Woo and PRoFESS Study Grp and PRoFESS Study Group and Sahlgrenska akademin and Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin and Institute of Medicine, Department of Emergeny and Cardiovascular Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The New England Journal of Medicine, ISSN 0028-4793, 09/2008, Volume 359, Issue 12, pp. 1238 - 1251
In this large clinical trial, aspirin plus extended-release dipyridamole was found to have an efficacy similar to that of clopidogrel in the prevention of... 
ISSUES | MEDICINE, GENERAL & INTERNAL | PLACEBO | DESIGN | TICLOPIDINE | WARFARIN | TRANSIENT ISCHEMIC ATTACK | DOUBLE-BLIND | PREVENTION | REGIMENS | NON-INFERIORITY TRIALS | Myocardial Infarction - epidemiology | Benzoates - therapeutic use | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Risk | Secondary Prevention | Aspirin - administration & dosage | Vascular Diseases - mortality | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Benzimidazoles - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Brain Ischemia - epidemiology | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Ischemia - prevention & control | Factor Analysis, Statistical | Stroke - drug therapy | Ticlopidine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Stroke (Disease) | Aspirin | Usage | Care and treatment | Dipyridamole | Clopidogrel | Health aspects | Stroke | Index Medicus | Abridged Index Medicus | Recurrence | Brain Ischemia | Benzimidazoles | Follow-Up Studies | Neurons and Cognition | Cognition | Hemorrhage | Drug Delivery Systems | Life Sciences | Angiotensin II Type 1 Receptor Blockers | Angiotensin-Converting Enzyme Inhibitors | Vascular Diseases | Mental Status Schedule | Retrospective Studies | Severity of Illness Index | Disability Evaluation | Benzoates | Drug Administration Schedule | International Cooperation | Ticlopidine | Myocardial Infarction | Platelet Aggregation Inhibitors | Santé publique et épidémiologie | Original | Dipyridamole/adverse effects/therapeutic use | Angiotensin-Converting Enzyme Inhibitors/therapeutic use | Recurrence/prevention & control | Benzoates/therapeutic use | Brain Ischemia/epidemiology/prevention & control | MEDICIN OCH HÄLSOVETENSKAP | Platelet Aggregation Inhibitors/administration & dosage/adverse | Combination | MEDICAL AND HEALTH SCIENCES | Aspirin/administration & dosage/adverse effects | Myocardial Infarction/epidemiology | Factor Analysis | Benzimidazoles/therapeutic use | Drug Therapy | Ticlopidine/adverse effects/analogs & derivatives/therapeutic use | effects/therapeutic use | Vascular Diseases/mortality | Hemorrhage/chemically induced | Stroke/drug therapy/epidemiology/prevention & control | Statistical | Kaplan-Meiers Estimate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC
by Mohammad, Helai P and Smitheman, Kimberly N and Kamat, Chandrashekhar D and Soong, David and Federowicz, Kelly E and Van Aller, Glenn S and Schneck, Jess L and Carson, Jeffrey D and Liu, Yan and Butticello, Michael and Bonnette, William G and Gorman, Shelby A and Degenhardt, Yan and Bai, Yuchen and McCabe, Michael T and Pappalardi, Melissa B and Kasparec, Jiri and Tian, Xinrong and McNulty, Kenneth C and Rouse, Meagan and McDevitt, Patrick and Ho, Thau and Crouthamel, Michelle and Hart, Timothy K and Concha, Nestor O and McHugh, Charles F and Miller, William H and Dhanak, Dashyant and Tummino, Peter J and Carpenter, Christopher L and Johnson, Neil W and Hann, Christine L and Kruger, Ryan G
Cancer Cell, ISSN 1535-6108, 07/2015, Volume 28, Issue 1, pp. 57 - 69
Epigenetic dysregulation has emerged as an important mechanism in cancer. Alterations in epigenetic machinery have become a major focus for targeted therapies.... 
CELL LUNG-CANCER | STEM-CELLS | THERAPEUTIC STRATEGY | DEMETHYLASE LSD1 | GENE | ONCOLOGY | EPIGENETIC REGULATION | ACUTE MYELOID-LEUKEMIA | DIFFERENTIATION | HISTONE MODIFICATIONS | EXPRESSION | CELL BIOLOGY | Lung Neoplasms - drug therapy | Histone Demethylases - antagonists & inhibitors | Humans | Molecular Sequence Data | Lung Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Histone Demethylases - genetics | Small Cell Lung Carcinoma - drug therapy | Enzyme Inhibitors - administration & dosage | Cyclopropanes - administration & dosage | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Cyclopropanes - pharmacology | Lung Neoplasms - genetics | Administration, Oral | Enzyme Inhibitors - pharmacology | Small Cell Lung Carcinoma - genetics | Benzoates - administration & dosage | Xenograft Model Antitumor Assays | Small Cell Lung Carcinoma - pathology | Animals | Benzoates - pharmacology | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | DNA Methylation - drug effects | Epigenetic inheritance | Lung cancer | DNA | Lysine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia
by Fisher, Sheila A and Fisher, Sheila A and Brunskill, Susan J and Brunskill, Susan J and Doree, Carolyn and Doree, Carolyn and Gooding, Sarah and Gooding, Sarah and Chowdhury, Onima and Chowdhury, Onima and Roberts, David J and Roberts, David J
The Cochrane database of systematic reviews, ISSN 1469-493X, 2013, Volume 8, Issue 12, p. CD004450
Background Thalassaemia major is a genetic disease characterised by a reduced ability to produce haemoglobin. Management of the resulting anaemia is through... 
Humans | Iron Overload [drug therapy; etiology] | LONG-TERM THERAPY | Pyridones [therapeutic use] | SUBCUTANEOUS BOLUS INJECTION | Chelation Therapy | DEFERIPRONE L1 | RANDOMIZED CONTROLLED-TRIAL | MYOCARDIAL IRON | Deferoxamine [administration & dosage] | Randomized Controlled Trials as Topic | TRANSFERRIN-BOUND IRON | MEDICINE, GENERAL & INTERNAL | Blood Transfusion [adverse effects] | RIGHT-VENTRICULAR FUNCTION | Thalassemia [therapy] | BETA-THALASSEMIA | COMBINED CHELATION-THERAPY | Iron Chelating Agents [administration & dosage] | MAJOR PATIENTS | Thalassemia - therapy | Triazoles - administration & dosage | Iron Overload - drug therapy | Deferiprone | Deferoxamine - administration & dosage | Benzoates - administration & dosage | Transfusion Reaction | Deferasirox | Iron Overload - etiology | Pyridones - administration & dosage | Iron Chelating Agents - administration & dosage | Siderophores - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights